ArticleThe Journal of pharmacology and experimental therapeutics2019
Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel
Article in The Journal of pharmacology and experimental therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys.Psychopharmacology · 2025Article
- Methocinnamox is a Potent and Long-Acting Antagonist that can Prevent and Reverse Opioid-Induced Respiratory Depression.The Journal of pharmacology and experimental therapeutics · 2024Article
- Comparison of theThe Journal of pharmacology and experimental therapeutics · 2024Article
- Daily methocinnamox treatment dose-dependently attenuates fentanyl self-administration in rhesus monkeys.Neuropharmacology · 2024Article
- Interactions between lorcaserin and opioids: Ventilation and food-versus-drug choice.Pharmacology, biochemistry, and behavior · 2024Article
- Evaluating the rate of reversal of fentanyl-induced respiratory depression using a novel long-acting naloxone nanoparticle, cNLX-NP.Frontiers in psychiatry · 2024Article
- Targeting Opioid Receptors in Addiction and Drug Withdrawal: Where Are We Going?International journal of molecular sciences · 2023Review
- Attenuation of the Positive-Reinforcing Effects of Ultra-Potent Fentanyl Analogs, Along with Those of Fentanyl and Heroin, During Daily Treatment with Methocinnamox in Rhesus Monkeys.The Journal of pharmacology and experimental therapeutics · 2023Article
- Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder.Journal of the experimental analysis of behavior · 2023Article
- The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder.Neuropharmacology · 2023Review
- Effects of Daily Methocinnamox Treatment on Fentanyl Self-Administration in Rhesus Monkeys.The Journal of pharmacology and experimental therapeutics · 2022Article
- The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review.Pharmacy (Basel, Switzerland) · 2022Review
- Methocinnamox Reverses and Prevents Fentanyl-Induced Ventilatory Depression in Rats.The Journal of pharmacology and experimental therapeutics · 2021Article
- Translational value of non-human primates in opioid research.Experimental neurology · 2021Review
- Countermeasures for Preventing and Treating Opioid Overdose.Clinical pharmacology and therapeutics · 2021Review
- The lasting impact of methocinnamox on opioid self-administration.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Article
- Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys.Psychopharmacology · 2020Article
- Acute and chronic stress prevents responses to pain in zebrafish: evidence for stress-induced analgesia.The Journal of experimental biology · 2020Article
- National Institutes of Health (NIH) Executive Meeting Summary: Developing Medical Countermeasures to Rescue Opioid-Induced Respiratory Depression (a Trans-Agency Scientific Meeting)-August 6/7, 2019.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2020Article
- Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects ofThe Journal of pharmacology and experimental therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
One consequence of the ongoing opioid epidemic is a large number of overdose deaths. Naloxone reverses opioid-induced respiratory depression; however, its short duration of action limits the protection it can provide. Methocinnamox (MCAM) is a novel opioid receptor antagonist with a long duration of action. This study examined the ability of MCAM to prevent and reverse the respiratory-depressant effects (minute volume [V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.